Table 2.
Medication Adherence During Intervention and Follow-Up, LDL Change from Baseline to 6 Months, and Survey Changes from Baseline to 3 Months and from 4 to 6 Months
| Control (n = 36) | Individual feedback (n = 36) | Feedback + Partner (n = 54) | |
|---|---|---|---|
| Intervention (0–3 months) adherence rate | 0.67 (0.60, 0.75) | 0.89 (0.81, 0.97) | 0.86 (0.80, 0.92) |
| p-value* | < 0.001 | 0.001 | |
| Follow-up (4–6 months) adherence rate | 0.54 (0.43, 0.66) | 0.60 (0.49, 0.72) | 0.52 (0.42, 0.61) |
| p-value* | 0.75 | 0.95 | |
| Change in LDL at 6 months | −9.14 (−19.47, 1.18) | −5.01 (−15.49, 5.48) | −4.60 (−13.55, 4.35) |
| p-value* | 0.85 | 0.79 | |
| Change in PAM level, baseline to 3 months† | 0.12 (−0.21, 0.45) | 0.23 (−0 01, 0 55) | 0.27 (0.01, 0.53) |
| p-value* | 0.88 | 0.77 | |
| Change in PAM level, 4 to 6 months | −0.14 (−0.43, 0.15) | −0.27 (−0.56, 0.02) | −0.32 (−0.55, −0.08) |
| p-value* | 0.82 | 0.63 | |
| Change in MSPSS level, baseline to 3 months‡ | −0.06 (−0.28, 0.15) | −0.09 (−0.31, 0.13) | −0.01 (−0.18, 0.17) |
| p-value* | 0.98 | 0.92 | |
| Change in MSPSS level, 4 to 6 months | 0.16 (−0.03, 0.35) | −0.01 (−0.20, 0.18) | 0.11 (−0.06, 0.28) |
| p-value* | 0.41 | 0.89 |
LDL low-density lipoprotein, PAM Patient Activation Measure, MSPSS Multidimensional Scale of Perceived Social Support *p-values reflect comparisons with control group, and are adjusted for multiple comparisons using the Tukey method. Differences between intervention arms were not significant.†PAM level range: 1 to 4‡MSPSS level range: 1 to 3